Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)

Market Cap	4.15B +2.6%
Revenue (ttm)	642.66M -10.9%
Net Income	136.31M -40.7%
EPS	0.69 -40.7%
Shares Out	198.24M
PE Ratio	30.23
Forward PE	n/a
Dividend	0.27 (1.29%)
Ex-Dividend Date	Jun 6, 2025

Volume	5,829,000
Average Volume	3,988,083
Open	21.10
Previous Close	21.36
Day's Range	20.65 - 21.21
52-Week Range	18.22 - 23.66
Beta	0.35
RSI	50.19
Earnings Date	Apr 25, 2026

About SHA:603896

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products under the Shouxiangu brand. Zhejiang Shouxiangu Pharmaceutical Co., Ltd. was founded in 1997 and is headquartered in Jinhua, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,118
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603896

Financial Performance

In 2024, SHA:603896's revenue was 691.68 million, a decrease of -11.81% compared to the previous year's 784.35 million. Earnings were 174.71 million, a decrease of -31.34%.